全部文献期刊学位论文会议报纸专利标准年鉴图书|学者科研项目
中外文文献  中文文献  外文文献
作者:Ghassan K. Abou-Alfa , Lionel D. Lewis , Patricia LoRusso ...
来源:[J].Cancer Chemotherapy and Pharmacology(IF 2.795), 2017, Vol.80 (1), pp.29-36Springer
摘要:Vismodegib is a Hedgehog pathway inhibitor approved for the treatment of advanced basal cell carcinoma. Currently, the pharmacokinetics (PK) and safety of vismodegib in patients with hepatic dysfunction are unknown and are the objective of this study.
作者:Motoo Nomura , Atsushi Otsuka , Tomohiro Kondo ...
来源:[J].Cancer Chemotherapy and Pharmacology(IF 2.795), 2017, Vol.80 (5), pp.999-1004Springer
摘要:Nivolumab is a monoclonal antibody directed against programmed death-1 that has been shown to improve survival in patients with metastatic melanoma. However, the efficacy of nivolumab and other agents in melanoma remains limited. The objective of this study was to evaluate the ef...
作者:Allen Lee Cohn , Takayuki Yoshino , Volker Heinemann ...
来源:[J].Cancer Chemotherapy and Pharmacology(IF 2.795), 2017, Vol.80 (3), pp.599-608Springer
摘要:To characterize ramucirumab exposure–response relationships for efficacy and safety in patients with metastatic colorectal cancer (mCRC) using data from the RAISE study.
作者:Melissa E. Badowski
来源:[J].Cancer Chemotherapy and Pharmacology(IF 2.795), 2017, Vol.80 (3), pp.441-449Springer
摘要:Oral cannabinoids (i.e., dronabinol, nabilone) containing the active component of marijuana, delta(Δ)9-tetrahydrocannabinol (THC), are available for the treatment of chemotherapy-induced nausea and vomiting (CINV) in patients with cancer who have failed to adequately respond...
作者:Howard A. Burris , C. D. Kurkjian , L. Hart ...
来源:[J].Cancer Chemotherapy and Pharmacology(IF 2.795), 2017, Vol.80 (2), pp.261-273Springer
摘要:This phase I trial evaluated the safety, pharmacokinetic profile, and antitumor activity of investigational oral TORC1/2 inhibitor TAK-228 plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies.
作者:Kaiming Ren , Ran Xu , Jingshan Huang ...
来源:[J].Cancer Chemotherapy and Pharmacology(IF 2.795), 2017, Vol.80 (2), pp.243-250Springer
摘要:Lung cancer, with the highest morbidity and second highest death rates, is one of the most common cancers in both males and females worldwide. Lung adenocarcinoma (LAD) is the main lung cancer class. KCNQ1 Opposite Strand/Antisense Transcript 1 (KCNQ1OT1) gene is an lncRNA which ...
作者:Munetaka Takekuma , Keita Mori , Tetsuji Iida ...
来源:[J].Cancer Chemotherapy and Pharmacology(IF 2.795), 2017, Vol.80 (4), pp.697-705Springer
摘要:This study aimed at evaluating the applicability of the concept of platinum sensitivity to recurrent cervical cancer.
作者:Makoto Ueno , Chung Pin Li , Masafumi Ikeda ...
来源:[J].Cancer Chemotherapy and Pharmacology(IF 2.795), 2017, Vol.80 (2), pp.307-315Springer
摘要:We investigated the efficacy and safety of 60, 120, or 240 mg of Z-360, which is a highly potent cholecystokinin2-receptor-selective antagonist, combined with gemcitabine in patients with metastatic pancreatic cancer.
作者:Cody J. Peer , Jung-Min Lee , Jeffrey Roth ...
来源:[J].Cancer Chemotherapy and Pharmacology(IF 2.795), 2017, Vol.80 (1), pp.165-175Springer
摘要:Combining olaparib with carboplatin was recently shown to be active in both BRCA and non- BRCA mutant cancers in a recent phase I/Ib combination trial. The optimal drug sequence recommended was carboplatin 1-day before olaparib. However, carboplatin pre-treatment induced a ~50% f...

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×